Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Gland Pharma's Hyderabad-based Pashamylaram facility has received three observations from the U.S. Food and Drug Administration (FDA) following a recent inspection. The FDA issued Form 483, detailing the observations, as confirmed by multiple sources including an exchange filing.
US FDA issues Form 483 with 3 observations for Gland Pharma's Hyderabad facility https://t.co/D4ptTj1xh1
U.S. #FDA inspection at #GlandPharma's #Hyderabad facility closes with 3 observations: Exchange filing
#JustIn | Gland Pharma: US FDA issues form 483 with 3 observations for co’s Hyderabad-based Pashamylaram facility Here's more👇 https://t.co/i2X5S1dl2k